All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site aml-hub.com.
2020-11-24T17:15:04.000Z

How can cytogenetics predict response to venetoclax and azacitidine in MDS?

By Claire Baker
Featured
Jacqueline S. Garcia
Nov 24, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How can cytogenetics predict response to venetoclax and azacitidine in MDS?

How can cytogenetics predict response to venetoclax and azacitidine in MDS?

Venetoclax is an orally bioavailable BCL-2 inhibitor that has demonstrated promising efficacy in combination with azacitidine. Here, Jacqueline Garcia discusses the ongoing phase Ib clinical trial, M15531 (NCT02942290), evaluating the safety and efficacy of venetoclax + azacitidine in patients with treatment-naïve, higher-risk MDS, and subgroup analyses.

More about...
AzacitidineEHAEHA 2020TP53Venetoclax

Related articles

Add bookmark

Phase I results of venetoclax combined with azacitidine in high-risk MDS or CMML

During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Alexandre Bazinet1 presented phase I results of the combination of venetoclax and...

Feb 10, 2022
Add bookmark

Phase I results of venetoclax combined with azacitidine in high-risk MDS or CMML

During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Alexandre Bazinet1 presented phase...

Feb 10, 2022
Add bookmark

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

The GFM-APR trial (NCT03931291) is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant AML or MDS following allo-SCT.

Jul 30, 2020
Add bookmark

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

The GFM-APR trial (NCT03931291) is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients...

Jul 30, 2020

Newsletter

Subscribe to get the best content related to MDS delivered to your inbox